|Last Price$35.53||Day Change (%)0.82%|
|Open Price$35.30||Day Change ($)0.29|
|Day Range35.21–35.55||52-Week Range27.72–36.66|
As of Thu 12/8/2016 12:11:00 PM | USD
Genentech’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to Rituxan
Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors
Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors
Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the 58th Annual Meeting of the American Society of Hematology
New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Sunovion to Initiate Recruitment for Aptiom® (eslicarbazepine acetate) Clinical Study with Integrated Digital Health Technology to Aid Seizure Detection
Late-Breaking Oral Plenary Presentation of a Novel Entrectinib Combination Regimen at the 2016 EORTC-NCI-AACR Annual Meeting
While more than one third of these top fund managers are outperforming this year, four of them stand out from the rest given their ability to outperform the market over almost all time periods.
Pepco deal, power prices, capacity markets, carbon caps: It’s been a wild ride for Exelon in 2014.